Cytokeratin 8 protects from hepatotoxicity, and its ratio to cytokeratin 18 determines the ability of hepatocytes to form Mallory bodies

American Journal of Pathology

Volumn 156, Issue 4, 2000, Pages 1263-1274

  Zatloukal, Kurt ^a   Stumptner, Cornelia ^a   Lehner, Manfred ^a   Denk, Helmut ^a   Baribault, Helene ^b   Eshkind, Leonid G ^c   Franke, Werner W ^c  

^a UNIVERSITY OF GRAZ   (Austria)

^b BURNHAM INSTITUTE   (United States)

^c GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALCOHOL; CYTOKERATIN; RNA;

ALCOHOL LIVER DISEASE; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; GENE EXPRESSION; IMMUNOHISTOCHEMISTRY; INTOXICATION; LIVER CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA SEQUENCE;

EID: 0033843879     PISSN: 00029440     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9440(10)64997-8     Document Type: Article

References (91)

1. Antibody to prekeratin. Decoration of tonofilament-like arrays in various cells of epithelial character
2. Different intermediate-sized filaments distinguished by immunofluorescence microscopy
3. Identification and characterization of epithelial cells in mammalian tissues by immunofluorescence microscopy using antibodies to prekeratin
4. Characterization of the intermediate-sized filaments in liver cells by immuno-fluorescence and electron microscopy
5. Keratin cytoskeletons in epithelial cells of internal organs
6. Characterization of human cytokeratin 2, an epidermal cytoskeletal protein synthesized late during differentiation
7. Suprabasal marker proteins distinguishing keratinizing squamous epithelia: Cytokeratin 2 polypeptides of oral masticatory epithelium and epidermis are different
8. Intermediate filaments: Structure, dynamics, function, and disease
9. Two distinct classes of epidermal keratin genes and their evolutionary significance
10. The catalog of human cytokeratins: Patterns of expression in normal epithelia, tumors and cultured cells
11. Heterotypic tetramer (A2D2) complexes of non-epidermal keratins isolated from cytoskeletons of rat hepatocytes and hepatoma cells
12. Pair formation and promiscuity of cytokeratins: Formation in vitro of heterotypic complexes and intermediate-sized filaments by homologous and heterologous recombinations of purified polypeptides
13. Elucidating the early stages of keratin filament assembly
14. The coiled-coil of in vitro assembled keratin filaments is a heterodimer of type I and II keratin: Use of site-specific mutagenesis and recombinant protein expression
15. The two-chain coiled-coil molecule of native epidermal keratin intermediate filaments is a type I-type II heterodimer
16. Heterotypic interactions and filament assembly of type I and type II cytokeratins in vitro: Viscometry and determinations of relative affinities
17. Intermediate filaments in disease
18. The cytoskeleton and disease: Genetic disorders of intermediate filaments
19. The basal keratin network of stratified squamous epithelia: Defining K15 function in the absence of K14
20. A human keratin 14 'knockout': The absence of K14 leads to severe epidermolysis bullosa simplex and a function for an intermediate filament protein
21. A functional 'knockout' of human keratin 14
22. A structural scaffolding of intermediate filaments in health and disease
23. Gene targeting at the mouse cytokeratin 10 locus: Severe skin fragility and changes of cytokeratin expression in the epidermis
24. HeLa cells contain intermediate-sized filaments of the prekeratin type
25. Biochemical and immunological identification of cytokeratin proteins present in hepatocytes of mammalian liver tissue
26. Differences of expression of cytoskeletal proteins in cultured rat hepatocytes and hepatoma cells
27. Diversity of cytokeratins. Differentiation specific expression of cytokeratin polypeptides in epithelial cells and tissues
28. Constitutive aggregates of intermediate-sized filaments of the vimentin and cytokeratin type in cultured hepatoma cells and their dispersal by butyrate
29. Biochemical and immunocytochemical analysis of the intermediate filament cytoskeleton in human hepatocellular carcinomas and in hepatic neoplastic nodules of mice
30. Monoclonal antibodies against trophectoderm-specific markers during mouse blastocyst formation
31. Formation of cytoskeletal elements during mouse embryogenesis
32. Formation of cytoskeletal elements during mouse embryogenesis. II. Epithelial differentiation and intermediate-sized filaments in early postimplantation embryos
33. Reactivity of monoclonal antibodies against intermediate filament proteins during embryonic development
34. Intermediate-size filaments in germ cells: Expression of cytokeratins in oocytes and eggs of the frog Xenopus
35. Intermediate filament protein synthesis in preimplantation murine embryos
36. Cytokeratin filament assembly in the pre-implantation mouse embryo
37. Chronic hepatitis, hepatocyte fragility, and increased soluble phosphoglycokeratins in transgenic mice expressing a cytokeratin 18 conserved arginine mutant
38. Susceptibility to hepatotoxicity in transgenic mice that express a dominant-negative human keratin 18 mutant
39. Mutation of human keratin 18 in association with cryptogenic cirrhosis
40. Mutation of a major keratin phosphorylation site predisposes to hepatotoxic injury in transgenic mice
41. Intermediate filament proteins of the liver: Emerging disease association and functions
42. Lessons from keratin 18 knockout mice: Formation of novel keratin filaments, secondary loss of keratin 7 and accumulation of liver-specific keratin 8-positive aggregates
43. Simple epithelium keratins are required for maintenance of hepatocyte integrity
44. Protein phosphatase inhibition in normal and keratin 8/18 assembly-incompetent mouse strains supports a functional role of keratin intermediate filaments in preserving hepatocyte integrity
45. Mid-gestational lethality in mice lacking keratin 8
46. Colorectal hyperplasia and inflammation in keratin 8-deficient FVB/N mice
47. Keratin modifications and solubility properties in epithelial cells and in vitro
48. Mallory bodies in experimental animals and man
49. Pathology of cytoskeleton of liver cells: Demonstration of Mallory bodies (alcoholic hyalin) in murine and human hepatocytes by immunofluorescence microscopy using antibodies to cytokeratin polypeptides from hepatocytes
50. Immunological and biochemical characterization of the keratin-related component of Mallory bodies: A pathological pattern of hepatocytic cytokeratins
51. Pathology of alcoholic liver disease
52. The Mallory body: Morphological, clinical and experimental studies (Part 1 of a literature survey)
53. The Mallory body: Theories on development and pathological significance (Part 2 of a literature survey)
54. Changes in the cytokeratin intermediate filament cytoskeleton associated with Mallory body formation in mouse and human liver
55. Ubiquitin is a common factor in intermediate filament inclusion bodies of diverse type in man, including those of Parkinson's disease, Pick's disease, and Alzheimer's disease, as well as Rosenthal fibers in cerebellar astrocytomas, cytoplasmic bodies in muscle, and Mallory bodies in alcoholic liver disease
56. Ubiquitin is present on the cytokeratin filaments and Mallory bodies of hepatocytes
57. Common epitopes of human and murine Mallory bodies and Lewy bodies as revealed by a neurofilament antibody
58. High molecular weight component of Mallory bodies detected by a monoclonal antibody
59. High molecular weight components are main constituents of Mallory bodies isolated with a fluorescence activated cell sorter
60. Rearrangement of the hepatocyte cytoskeleton after toxic damage: Involution, dispersal and peripheral accumulation of Mallory body material after drug withdrawal
61. Maintenance of desmosomes in mouse hepatocytes after drug-induced rearrangement of cytokeratin filament material
62. Change of cytokeratin organization during development of Mallory bodies as revealed by a monoclonal antibody
63. Fate of Mallory body-containing hepatocytes: Disappearance of Mallory bodies and restoration of the hepatocytic intermediate filament cytoskeleton after drug withdrawal in the griseofulvin-treated mouse
64. Hepatocellular hyalin (Mallory bodies) in long term griseofulvin-treated mice: A new experimental model for the study of hyalin formation
65. Ultrastructural, biochemical, and immunologic characterization of Mallory bodies in livers of griseofulvin-treated mice. Fimbrated rods of filaments containing precytokeratin-like polypeptides
66. Cytoskeletal alterations leading to Mallory body formation in livers of mice fed 3, 5-diethoxy-carbonyl-1, 4-dihydrocollidine
67. Expression of retroviral vectors in transgenic mice obtained by embryo infection
68. Characterization of a second highly conserved B-type lamin present in cells previously thought to contain only a single B-type lamin
69. Decreased levels of cytochrome P-450 and catalase in hepatic porphyria caused by substituted acetamides and barbiturates. Importance of the allyl group in the molecule of the active drugs
70. The simultaneous extraction of high molecular weight DNA and of RNA from solid tumors
71. Evaluation of different standard types for quantitative reverse transcription polymerase chain reaction: Possible pitfalls and strategies for avoidance
72. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding
73. Cleavage of structural proteins during the assembly of the head of bacteriophage T4
74. Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: Procedures and some applications
75. Identification of N-methylprotophorphyrin IX in livers of untreated mice and mice treated with 3, 5-diethoxycarbonyl-1, 4-dihydrocollidine: Source of the methyl group
76. N-Methylprotoporphytin IX: Chemical synthesis and identification as the green pigment produced by 3, 5-diethoxycarbonyl-1, 4-dihydrocollidine treatment
77. Ductular reaction in the liver
78. Modulation of protein composition of nuclear lamina
79. Hepatocellular cytokeratins as substrates of transglutaminase
80. Cytokeratin of apparent high molecular weight in livers from griseofulvin-fed mice
81. Non-alcoholic steatohepatitis (NASH): A disease of emerging identity and importance
82. The transfection of epidermal keratin genes into fibroblasts and simple epithelial cells: Evidence for inducing a type I keratin by a type II gene
83. A cytokeratin immunohistochemical study of alcoholic liver disease: Evidence that hepatocytes can express 'bile duct-type' cytokeratins
84. A cytokeratin immunohistochemical study of cholestatic liver disease: Evidence that hepatocytes can express 'bile duct-type' cytokeratins
85. Alcoholic liver disease. Parenchyma to stroma relationship in fibrosis and cirrhosis as revealed by three-dimensional reconstruction and immunohisto-chemistry
86. Expression of cytokeratin confers multiple drug resistance
87. Patterns of porphyrin accumulation in response to xenobiotics. Parallels between results in chick embryo and rodents
88. Stress, apoptosis, and mitosis induce phosphorylation of human keratin 8 at ser-73 in tissues and cultured cells
89. Heat stress or rotavirus infection of human epithelial cells generates a distinct hyperphosphorylated form of keratin 8
90. Pervanadate-mediated tyrosine phosphorylation of keratin 8 and 19 via a p38 mitogen-activated protein kinase-dependent pathway
91. Vimentin serves as a phosphate sink during the apparent activation of protein kinases by okadaic acid in mammalian cells